While coronavirus disease 2019 (COVID-19) is largely a respiratory disease, it is actually a systemic disease that has a wide range of effects and postinfection sequelae that aren’t yet fully known, said Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.
While coronavirus disease 2019 (COVID-19) is largely a respiratory disease, it is actually a systemic disease that has a wide range of effects and postinfection sequelae that aren’t yet fully known, said Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.
Transcript
There seems to be a range of symptoms for COVID-19, with some people getting blood clots and neurological symptoms, and then a minority of children are coming down with an autoimmune syndrome. Do you think this will always remain a respiratory disease or do you think it might someday become a systemic disease for some people?
Well, I think it already is a systemic disease for some people—we’re just not recognizing the full implications of the pathogenesis and the clinical manifestations. I mean, I don't think it necessarily is going to evolve to do more systemically, but I think what we'll likely see are more surprises like the multisystem inflammatory disease in children—MIS-C. I think we likely will see as time goes by some postinfection sequelae that we'll only realize as we do good follow up in natural history studies.
I mean, the scope of the seriousness of this infection is extraordinary—from people who get a stuffy nose and a little sore throat and ache, and they get better to people who spend 14 days with a sustained fever and come out wiped out with a postviral dystonia, to people who have serious lung involvement that either puts them in the hospital or creates intubation needs and intensive care…to people who die.
I mean, that range of severity is really in many respects unprecedented. So, I think we still have a lot to learn about the disease of COVID-19.
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH
April 1st 2025To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The April issue features a conversation with Hoangmai H. Pham, MD, MPH, a member of AJMC’s editorial board and the president and CEO of the Institute for Exceptional Care (IEC).
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More